Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 1:264:118617.
doi: 10.1016/j.lfs.2020.118617. Epub 2020 Oct 20.

Preventing the development of severe COVID-19 by modifying immunothrombosis

Affiliations
Review

Preventing the development of severe COVID-19 by modifying immunothrombosis

Gerwyn Morris et al. Life Sci. .

Abstract

Background: COVID-19-associated acute respiratory distress syndrome (ARDS) is associated with significant morbidity and high levels of mortality. This paper describes the processes involved in the pathophysiology of COVID-19 from the initial infection and subsequent destruction of type II alveolar epithelial cells by SARS-CoV-2 and culminating in the development of ARDS.

Main body: The activation of alveolar cells and alveolar macrophages leads to the release of large quantities of proinflammatory cytokines and chemokines and their translocation into the pulmonary vasculature. The presence of these inflammatory mediators in the vascular compartment leads to the activation of vascular endothelial cells platelets and neutrophils and the subsequent formation of platelet neutrophil complexes. These complexes in concert with activated endothelial cells interact to create a state of immunothrombosis. The consequence of immunothrombosis include hypercoagulation, accelerating inflammation, fibrin deposition, migration of neutrophil extracellular traps (NETs) producing neutrophils into the alveolar apace, activation of the NLRP3 inflammazome, increased alveolar macrophage destruction and massive tissue damage by pyroptosis and necroptosis Therapeutic combinations aimed at ameliorating immunothrombosis and preventing the development of severe COVID-19 are discussed in detail.

Keywords: COVID-19; Respiratory infection; SARS-CoV-2; Treatment.

PubMed Disclaimer

Conflict of interest statement

MB is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072). MB has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Australian Rotary Health, A2 Milk Company, Meat and Livestock Australia, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Astra Zeneca, Lundbeck, Merck, Pfizer, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer and Servier – all unrelated to this work. LO is supported by a NHMRC Early Career Fellowship (1158487). WM is currently funded by an Alfred Deakin Postdoctoral Research Fellowship and a Multiple Sclerosis Research Australia early-career fellowship. WM has previously received funding from the Cancer Council Queensland and university grants/fellowships from La Trobe University, Deakin University, University of Queensland, and Bond University. WM has received industry funding and has attended events funded by Cobram Estate Pty. Ltd. WM has received travel funding from Nutrition Society of Australia. WM has received consultancy funding from Nutrition Research Australia. WM has received speaker honoraria from The Cancer Council Queensland and the Princess Alexandra Research Foundation. The Food & Mood Centre has received Grant/Research support from Fernwood Foundation, Wilson Foundation, the A2 Milk Company, and Be Fit Foods. AO is supported by a Future Leader Fellowship (#101160) from the Heart Foundation Australia and Wilson Foundation. She has received research funding from National Health and Medical Research Council, Australian Research Council, University of Melbourne, Deakin University, Sanofi, Meat and Livestock Australia and Woolworths Limited and Honoraria from Novartis.

Figures

Unlabelled Image
Graphical abstract
Fig. 1
Fig. 1
The pathophysiology of COVID-19 ARDS. Initial infection and activation of type 2 alveolar cells and alveolar macrophages by SARS-CoV-2 results in the secretion of IL-6, PICs, NO and several chemokines which activate vascular endothelial cells platelets and neutrophils ultimately forming a platelet neutrophil complex. The interplay between vascular endothelial cells activated platelets and activated primed neutrophils produces a highly coagulative and inflammatory state described as immunothrombosis. The translocation of neutrophils and platelets into the pulmonary microvasculature results in severe epithelial layer damage alveolar fibrin deposition and the formation of microthrombi. The translocation of NET producing neutrophils into alveoli and lung interstitium coupled with their delayed apoptosis results in the development cytokine storm producing extreme tissue damage and often fatal lung dysfunction created by several feedforward loops involving interplay between PICS DAMPS ROS, activation of the NLRP3 inflammasome activation, alveolar macrophage pyroptosis, influx of inflammatory bone derived monocytes and necroptosis.
Fig. 2
Fig. 2
The effects of vitamin D on the immune system. Vitamin D inhibits B cell proliferation differentiation and immunoglobulin secretion. Vitamin D also suppresses T cell proliferation, TH17 differentiation increases levels of regulatory T cells and induces a tolerogenic Th2 phenotype. The sum of these effects is reduced levels of interleukin (IL)-17, IL-21 and IL-23 and increased levels of IL-10. Vitamin D also inhibits the maturation of dendritic cells and inhibits the production of pro inflammatory cytokines and chemokines from monocytes and macrophages reducing plasma levels of TNF-alpha, IL-1, IL-6, IL-12 and IL-8. In addition, Vitamin D activity stimulates the production of beta defensins and cathelicidin in monocytes and macrophages following pathogen invasion with forms an essential role in the anti-viral response.
Fig. 3
Fig. 3
The effects of Vitamin C on the immune system. Vitamin C enhances the activity of TET enzymes and Jumonji C domain-containing histone demethylases (JHDMs) thereby decreasing rates of DNA and histone methylation respectively and prevents the hyperactivity of HIF 1 alpha. The net effect of these actions involves increased macrophage phagocytosis decreased neutrophil necrosis and the differentiation of T cells into a TH2 phenotype increases levels of regulatory T cells and inhibits naive T cell differentiation into a Th17 phenotype. Vitamin C is needed for memory CD8 and CD4 T cell formation and optimal T lymphocyte function. Vitamin C supplementation also reduces IL-6 and MCP-1 production by macrophages and dendritic cells while inhibiting dendritic cell maturation.

Similar articles

Cited by

References

    1. de Wit E., van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016;14:523–534. - PMC - PubMed
    1. Liu J., Zheng X., Tong Q., Li W., Wang B., Sutter K. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J. Med. Virol. 2020;92:491–494. - PMC - PubMed
    1. He X., Lau E.H.Y., Wu P., Deng X., Wang J., Hao X. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 2020;26:672–675. - PubMed
    1. Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810. - PMC - PubMed
    1. Wu P., Duan F., Luo C., Liu Q., Qu X., Liang L. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138(5):575–578. - PMC - PubMed

MeSH terms